866-997-4948(US-Canada Toll Free)

Huntingtons Disease - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 38 Pages


GlobalData, the industry analysis specialist, has released its new report, Huntingtons Disease Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Huntingtons disease therapeutics market and pipeline. The report identifies the key trends shaping and driving the global huntingtons disease therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global muscular dystrophy therapeutics sector. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData has estimated the global Huntingtons disease therapeutics market to be valued at $142 m in 2009. It is expected to increase to $2 billion with a Compound Annual Growth Rate (CAGR) of 39.6 by 2017. There is a high unmet need in the current Huntingtons disease therapeutics market in terms of both safety and efficacy profile. New high potential drugs of Huntingtons disease therapeutics are expected to come in the market after 2017. 

Scope

The report provides information on the key drivers and challenges of the Huntingtons disease therapeutics market. Its scope includes: 

  • Annualized global Huntingtons disease therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major classes such as nerve growth factor and doparmegenic neurons loss inhibitor 
  • Analysis of the current and future competition in the global Huntingtons disease therapeutics market. Key market players covered are Amarin Corporation and Medivation Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Huntingtons disease therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Huntingtons disease therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Huntingtons disease market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Huntingtons disease market landscape? Identify, understand and capitalize.
Table of Content

1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 4

2 Huntingtons Disease: Market Characterization 5
2.1 Overview 5
2.2 Huntingtons Disease Therapeutics Market Size 6
2.3 Huntingtons Disease Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Huntingtons Disease Therapeutics Market 8
2.4.1 Drivers for the Huntingtons Disease Therapeutics Market 8
2.4.2 Barriers for the Huntingtons Disease market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10

3 Huntingtons Disease Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Huntingtons Disease Therapeutics Market 12
3.3.1 Xenazine (tetrabenazine) 12
3.4 Key Takeaway 13

4 Huntingtons Disease: Pipeline Assessment 14
4.1 Overview 14
4.2 Strategic Pipeline Assessment 14
4.2.1 Technology Trends Analytic Framework 14
4.3 Huntingtons Disease Therapeutics Promising Drugs under Clinical Development 16
4.4 Molecule Profile for Promising Drugs under Clinical Development 17
4.4.1 AMR-101 (Miraxion, ethyl EPA) (Amarin Pharmaceuticals) 17
4.4.2 Dimebon (latrepirdine) (Medivation/Pfizer) 18
4.4.3 Coenzyme Q10 (CoQ) (National Institute of Neurological Disorders and Stroke - NINDS) 19
4.5 Huntingtons Disease Therapeutics Clinical Pipeline by Mechanism of Action 20
4.5.1 Huntingtons Disease TherapeuticsPipeline Pipeline by Clinical Phases of Development 21
4.5.2 Huntingtons Disease Therapeutics Phase III Clinical Pipeline 21
4.5.3 Huntingtons Disease Therapeutics Phase II Clinical Pipeline 21
4.5.4 Huntingtons Disease Therapeutics Phase I Clinical Pipeline 22
4.5.5 Huntingtons Disease Therapeutics Preclinical Phase Pipeline 22
4.5.6 Huntingtons Disease Therapeutics Discovery Pipeline 22
4.6 Key Takeaway 23

5 Huntingtons Disease Therapeutics Market: Implications for Future Market Competition 24

6 Huntingtons Disease Therapeutics Market: Future Players in the Huntingtons Disease Market 26
6.1 Introduction 26
6.2 Amarin Corporation, Ireland 27
6.2.1 Overview 27
6.2.2 CNS Portfolio 27
6.2.3 Huntingtons disease Portfolio 27
6.3 Medivation Inc., the US 28
6.3.1 Overview 28
6.3.2 CNS Portfolio 29
6.3.3 Huntingtons Disease Portfolio 29
6.4 National Institute of Neurological Disorders and Stroke, the US 30
6.4.1 Overview 30
6.4.2 Huntingtons Disease Portfolio 30

7 Huntingtons Disease Market: Appendix 32
7.1 Market Definitions 32
7.2 Abbreviations 32
7.3 Research Methodology 33
7.3.1 Coverage 33
7.3.2 Secondary Research 34
7.3.3 Forecasting 34
7.3.4 Primary Research 37
7.3.5 Expert Panel Validation 37
7.4 Contact Us 37
7.5 Disclaimer 37
7.6 Sources 38

List of Table


Table 1: Huntingtons Disease Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Table 2: Huntingtons Disease Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 7
Table 3: Major Marketed Product in the Huntingtons Disease Therapeutics Market, 2010 13
Table 4: Huntingtons Disease Therapeutics Market Most Promising Drugs Under Clinical Development, 2010 16
Table 5: Huntingtons Disease Therapeutics Market, Phase III Clinical Pipeline, 2010 21
Table 6: Huntingtons Disease Therapeutics Market, Phase II Clinical Pipeline, 2010 21
Table 7: Huntingtons Disease Therapeutics Market, Phase I Clinical Pipeline, 2010 22
Table 8: Huntingtons Disease Therapeutics, Preclinical Phase Pipeline, 2010 22
Table 9: Huntingtons Disease Therapeutics Market Discovery Pipeline, 2010 22
Table 10: Amarin, CNS Pipeline Products, 2010 27
Table 11: Amarin, Huntingtons Disease Pipeline Products, 2010 27
Table 12: Medivation, CNS Pipeline Products, 2010 29
Table 13: Medivation, Huntingtons Disease Pipeline Products, 2010 29
Table 14: NINDS, Huntingtons Disease Pipeline Products, 2010 30

List of Chart


Figure 1: Huntingtons Disease Therapeutics Market, Global, Revenues ($m), 2001-2009 6
Figure 2: Huntingtons Disease Therapeutics Market, Global, Revenue Forecast ($m), 2009-2017 7
Figure 3: Opportunity and Unmet Need in the Huntingtons Disease Therapeutics Market 9
Figure 4: Strategic Competitor Assessment of the Marketed Products for the Huntingtons Disease Therapeutics Market, 2010 11
Figure 5: Technology Trends Analytic Framework of the Huntingtons Disease Therapeutics Market Pipeline, 2010 15
Figure 6: Technology Trends Analytic Framework of the Huntingtons Disease Therapeutics Market Pipeline, Description, 2010 15
Figure 7: Huntingtons Disease Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2010 20
Figure 8: Huntingtons Disease Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2010 21
Figure 9: Implications for Future Market Competition in the Huntingtons Disease Therapeutics Market, 2010 24
Figure 10: Huntingtons Disease Therapeutics Market, Clinical Pipeline by Company, 2010 26
Figure 11: GlobalData Market Forecasting Model 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *